Loren Data's SAM Daily™

FBO DAILY ISSUE OF APRIL 25, 2004 FBO #0881
MODIFICATION

99 -- Blood Products

Notice Date

4/23/2004
 

Notice Type

Modification
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, MD, 20817
 

ZIP Code

20817
 

Solicitation Number

NOI4064
 

Response Due

5/10/2004
 

Archive Date

5/25/2004
 

Point of Contact

Shirlene Smith, Purchasing Agent, Phone 301-402-6315, Fax 301-480-3695, - Sylvia Robinson, Purchasing Agent, Phone 301-402-2284, Fax 301-480-3695,
 

E-Mail Address

ssmith@niaid.nih.gov, srobinson@niaid.nih.gov
 

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are not being requested and a written solicitation will not be issued for solicitation number NOI4064. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2001-22. This acquisition will be processed under Simplified Acquisition Procedures (SAP) and is not a Small Business Concern. The associated North American Industry Classification System (NAICS) Code 325414, which has a size standard of 500. The National Institute of Allergy and Infectious Diseases intends to procure on a sole source basis from Hyclone Laboratories Inc., the only known source to provide this Lot #ANM20277 for 500ml bottles of Fetal Bovine Serum (FBS) quantity 300; 12 months storage/4 shipments. The laboratory has used FBS from Hyclone for over 15 years and have found their FBS to be consistently of a very high standard that is absolutely required in order to maintain and propagate the large number of different cell lines and primary cell cultures with diverse biological specificities that are used in by over 40 investigators in the laboratory. One of the primary research efforts in our laboratory is the development of a vaccine against human immunodeficiency virus type 1 (HIV-1). We have developed an animal model system that utilizes viral infected rhesus macaques to assess the protective efficacy of potential candidate HIV-1 vaccines. The ability to culture primary peripheral blood mononuclear cells (PBMC) and in vivo differentiated macrophages isolated directly from rhesus macaques is critical to this effort. Culture of the primary cells is essential in order to evaluate the immunological responses in the animals to different vaccine regimens. Prescreening of specific FBS lots is required in order to insure that the FBS selected will allow for the growth of the primary cells as well as propagation of the virus in these cells. The screening process is very time consuming and requires specialized techniques to successfully isolate and properly culture these specific primary cell types from the animals. The in vivo differentiated macrophage cultures are particularly sensitive to having the proper reagents and culture conditions. The specific Lot #ANM20277 Fetal Bovine Serum from Hyclone indicated above has be screened in this regard and has been found to meet the criteria required to be used in our ongoing vaccine studies. As the vaccine studies can take over three years to complete, are quite expensive to conduct and are currently ongoing, continuity in the quality of this essential tissue culture reagent is paramount to the successful continuance of our vaccine research. Anticipated Date of delivery ? May 10, 2004; place of delivery- NIH/NIAID, Maryland 20892; FOB origin. The following FAR provisions and clauses apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items. FAR 52.212.3 Offerors Representations and Certifications ? Commercial Items; FAR 52.212-4 Contractor Terms and Conditions ? Commercial Items; FAR 52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders ? Commercial Items. Offeror must include with their offer a completed copy of provisions at FAR 52.212-3 Offerors Representations and Certications ? Commercial Items. As prescribed in 4.1104, use the following clause (52.204-7), Central Contractor Registration (Oct 2003) ?Registered in the CCR database,? means that (1) The Contractor has entered all mandatory information, including the DUNS number or the DUNS+4 number, into the CCR database; and (2)The Government has validated all mandatory data fields and has marked the record ?Active.? (By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the CCR database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation). Registration is available via Internet at http://www.ccr.gov. Offer must be submitted no later than 5:00P.M. Eastern Daylight Time (EDT), May 10, 2004, to Shirlene Smith . Copies of the aforementioned clauses are available upon request by telephone to Shirlene Smith at (301)496-2607. For delivery through the Postal Service, the address is NIH/NIAID/AMOB, 10401 Fernwood Drive, Suite 2NE70, Room/2NE62F, MSC/4812, Bethesda, Maryland 20817-4812. Electronic submission will not be accepted. Requests for information concerning this requirement are to be addressed to Shirlene Smith (301)496-2607. Collect calls will not be accepted. All responsible sources may submit an offer that will be considered by this agency.
 

Place of Performance

Address: National Institutes of Health,, Bethesda, Maryland

Zip Code: 20892

Country: USA
 

Record

SN00571730-W 20040425/040423211836 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |